プロフィール詳細

プロジェクトを作成

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Dr. Akbar S.に依頼

United Kingdom

Haemato-oncology expert with 8+ years in translational research, scientific writing, ISO 15189 and biopharma valuation

プロフィール概要

Haemato-oncology expert with 8+ years translating mechanistic biology in myeloid malignancies into decision-ready outputs for clinicians, investors, and biotech teams. As one of Oxford’s youngest postdoctoral researchers at the University of Oxford’s Ludwig Cancer Research, I design and execute translational studies that integrate patient samples with multi-omics to pinpoint drug targets, resistance mechanisms, and biomarkers. This work contributed to a Nature Genetics publication and informed portfolio and trial design decisions, while reducing project setup times by 70% and cutting costs by 50% through streamlined experimental and analysis workflows. During my PhD in Medicine at the University of St Andrews, I advanced preclinical findings that supported a Phase I/II clinical trial, generated patent-supporting data, and presented results on international stages including EHA and AACR. These milestones demonstrate my ability to move hypotheses from bench to clinic, create assays that stand up to regulatory scrutiny, and communicate complex evidence in clear, actionable formats for scientific and commercial stakeholders. I bring diagnostic rigor from ISO 15189 environments. At NHS Glasgow Royal Infirmary I processed 8,000+ specimens within UKAS quality systems using LIMS, ALCOA+, CAPA, and EQA, maintaining audit readiness. That experience anchors my approach to assay validation, MRD strategies, and protocol optimisation, ensuring outputs that are reproducible and clinically relevant. I am fluent in FDA, EMA, MHRA, NICE, and ICB processes and have supported biopharma valuations. I build literature-grounded, model-driven assessments that combine rNPV, market sizing, pricing and access assumptions, and KOL insight to inform go or no-go choices. What I deliver: Study design for AML, MPN, MDS, CML, CMML, CLL, HL, and NHL, spanning small molecules, mAbs, bispecifics, CAR-T, ADCs, HMAs, PROTACs, and radioligands. Data analysis and visualisation in R and Excel, including NGS pipelines, MRD analytics, and figure preparation that is publication ready. Medical and scientific writing across manuscripts, reviews, grants, SOPs, slide decks, and regulatory-aware summaries. Biopharma diligence and valuation support that integrates evidence synthesis with clear, defensible financial models. Training includes a PhD in Medicine from St Andrews, an MRes with Distinction from the University of Glasgow, HCPC registration as a Biomedical Scientist, Good Clinical Practice (GCP) certification, and Strategy, Innovation, Scientific Entrepreneurship, and Financial Modelling modules completed at Oxford Saïd Business School.

専門分野

• ☆ Biochemistry
• ☆ Immunoassay
• ☆ Biochemical Assays
• ☆ Apoptosis
• ☆ Oxidative Stress & Mitochondrial Function
• ☆ Antioxidants
• ☆ Molecular Biology
• ☆ Biomarkers
• ☆ Genetics
• ☆ Molecular Evolution
• ☆ Chromatin
• ☆ Epigenetics
• ☆ PCR
• ☆ Molecular Cloning
• ☆ Next Generation Sequencing (NGS)
• ☆ ATAC-Seq
• ☆ DNA Sequencing
• ☆ Protein Sequencing
• ☆ Gene Expression Analysis
• ☆ Genome Sequencing
• ☆ Mutagenesis
• ☆ RNA Sequencing
• ☆ ChIP-Seq
• ☆ Cell Biology
• ☆ Cell-Based Assays
• ☆ Cytochemistry
• ☆ Cytogenetics
• ☆ Cell Signaling Pathways
• ☆ Membrane Biology
• ☆ Gene Regulation
• ☆ Stem Cell Research
• ☆ Histology
• ☆ Microscopy
• ☆ Light Microscopy
• ☆ Fluorescence Microscopy
• ☆ Biomarker Discovery
• ☆ Cell Culture
• ☆ Primary Cells
• ☆ Cell Banking
• ☆ Cell Line Engineering
• ☆ Large Scale Cell Culture
• ☆ Cell Surface Receptors
• ☆ Blotting
• ☆ Immunohistochemistry
• ☆ Cytometry
• ☆ Cell Aging
• ☆ Journalism
• ☆ R
• ☆ Drug Discovery
• ☆ Phenotypic Assays
• ☆ Drug Development
• ☆ Preclinical Research
• ☆ In vitro Preclinical Toxciology
• ☆ In vivo Preclinical Toxicology
• ☆ Clinical Trials
• ☆ Clinical Trial Design
• ☆ Precision Medicine
• ☆ Hematology
• ☆ Hematology-Oncology
• ☆ Leukemia & Lymphoma
• ☆ Presentation Design
• ☆ Technical & Scientific Writing
• ☆ Journal Selection
• ☆ Manuscript & Journal Article Writing
• ☆ Experimental Protocols
• ☆ SOP & Protocol Writing
• ☆ White Papers
• ☆ Case Studies
• ☆ Business Finance

サービス

• Writing
• Research
• Consulting
• Data & AI

Writing Clinical Trial Documentation, Medical Writing, Non-Medical Regulatory Writing, Technical Writing, Copywriting, Creative Writing, Newswriting, General Proofreading & Editing, Translation

Research Market Research, User Research, Meta-Research, Fact Checking, Gap Analysis, Gray Literature Search, Scientific and Technical Research, Systematic Literature Review, Secondary Data Collection

Consulting Business Strategy Consulting, Go-to-Market Strategy Consulting, Healthcare Consulting, Scientific and Technical Consulting

Data & AI Statistical Analysis, Image Processing, Image Analysis, Data Visualization, Data Mining

職務経験

University of Oxford

- 現在

Postdoctoral Research fellow

The University of Oxford

9月 2022 - 現在

学歴

PhD Medicine

The University of St Andrews

9月 2019 - 9月 2022

MRes Biomedical Sciences

The University of Glasgow

9月 2018 - 8月 2019

BSc (Hons) Applied Biomedical Science

Glasgow Caledonian University

9月 2014 - 5月 2018

認定資格

• Good Clinical Practice (GCP)

  The University of Oxford

  7月 2025 - 現在

• Strategy & Innovation

  The University of Oxford

  7月 2025 - 現在

• Scientific Entrepreneurship and Financial Modelling

  The University of Oxford

  9月 2024 - 現在

• IBMS Certificate of Competence

  Institute of Biomedical Science

  7月 2018 - 現在

出版物

JOURNAL ARTICLE

Akbar M. Shahid, William Vainchenker, Stefan N. Constantinescu (2025). JCMM Annual Review on Advances in Biotechnology for the Treatment of Haematological Malignancies: A Review of the Latest In‐Patient Developments 2024–2025 . Journal of Cellular and Molecular Medicine.

Akbar M. Shahid, William Vainchenker, Stefan N. Constantinescu (2025). JCMM Annual Review on Advances in Biotechnology for the Treatment of Haematological Malignancies: A Review of the Latest In‐Patient Developments 2024–2025 . Journal of Cellular and Molecular Medicine.

Tomkova M, McClellan MJ, Crevel G, Shahid AM, Mozumdar N, Tomek J, Shepherd E, Cotterill S, Schuster-Böckler B, Kriaucionis S (2024). Human DNA polymerase ε is a source of C>T mutations at CpG dinucleotides . Nature genetics.

Shahid AM, Um IH, Elshani M, Zhang Y, Harrison DJ (2022). NUC-7738 regulates β-catenin signalling resulting in reduced proliferation and self-renewal of AML cells . PloS one.